Author

R. Ceccaldi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Gelot· 2 shared H. Yucel· 2 shared A. D. D'Andrea· 1 shared A. Farkkila· 1 shared A. Li· 1 shared A. Syed· 1 shared B. Kochupurakkal· 1 shared B. S. Blagg· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. Gelot

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Polθ is phosphorylated by Polo-like kinase 1 (PLK1) to enable repair of DNA double strand breaks in mitosis

C. Gelot, M. T. Kovacs, S. Miron, E. Mylne, R. Ghouil, T. Popova, F. Dingli, D. Loew, J. Guirouilh-Barbat, E. Del Nery, S. Zinn-Justin, R. Ceccaldi

This study identifies Polθ as a key factor in repairing DNA double strand breaks during mitosis, showing that its phosphorylation by PLK1 enables this process and maintains genome integrity.

bioRxiv · Mar 17, 2023Cell Biology

Nuclear NAD+ homeostasis is essential for naive and chemoresistant BRCA1/2-deficient tumor survival

D. Musiani, H. Yucel, L. Sourd, E. Marangoni, R. Ceccaldi

This study identifies NMNAT1 as a therapeutic target for BRCA1/2-deficient tumors, showing its synthetic lethality with BRCA1/2 in a PARP1-independent but SIRT6-dependent manner.

bioRxiv · Dec 9, 2021Cancer Biology

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

J. Zhou, C. Gelot, C. Pantelidou, A. Li, H. Yucel, R. E. Davis, A. Farkkila, B. Kochupurakkal, A. Syed, G. I. Shapiro, J. A. Tainer, B. S. Blagg, R. Ceccaldi, A. D. D'Andrea

The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.

bioRxiv · May 23, 2020Cancer Biology